| Literature DB >> 29867469 |
Mei Kee Lee1, Xiaojie Li2, Alvin Chee Sum Yap3, Peter Chi Keung Cheung2, Chon Seng Tan4, Szu Ting Ng4, Richard Roberts5, Kang Nee Ting1, Shin Yee Fung3,6.
Abstract
Lignosus rhinocerotis has a long history of use by the indigenous community within East Asia to treat a range of health conditions including asthma and chronic cough. To date, there is limited scientific evidence to support its therapeutic effects in relieving these airways conditions. In this study, we examined the effects of the different molecular weight fractions [high-molecular-weight (HMW), medium-molecular-weight (MMW), and low-molecular-weight (LMW)] obtained from the cold water sclerotial extract (CWE) of L. rhinocerotis on airways patency using airway segments isolated from Sprague Dawley rat in an organ bath set-up. It is demonstrated that the HMW and MMW fractions exhibited higher efficacy in relaxing the pre-contracted airways when compared to the CWE and LMW fraction. In addition, the HMW fraction markedly supressed carbachol-, 5-hydroxytrptamine-, and calcium-induced airway contractions. CWE demonstrated a lower efficacy than the HMW fraction but it also significantly attenuated carbachol- and calcium-induced airway contractions. Results showed that the bronchorelaxation effect of CWE and fractions is mediated via blockade of extracellular Ca2+ influx. The composition analysis revealed the following parts of carbohydrate and proteins, respectively: HMW fraction: 71 and 4%; MMW fraction: 35 and 1%; and LMW fraction: 22 and 0.3%. Our results strongly suggest that the polysaccharide-protein complex or proteins found in the HMW and MMW fractions is likely to contribute to the bronchorelaxation effect of CWE.Entities:
Keywords: Lignosus rhinocerotis; airway diseases; aqueous extract; bronchorelaxation; fractions; medicinal mushroom; tiger milk mushroom
Year: 2018 PMID: 29867469 PMCID: PMC5949369 DOI: 10.3389/fphar.2018.00461
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Chemical composition and monosaccharide profile of CWE and its fractions.
| Sample | Protein % | Total carbohydrate % | Monosaccharides (normalised %) | ||||
|---|---|---|---|---|---|---|---|
| Arabinose | Xylose | Mannose | Galactose | Glucose | |||
| TM02 sclerotial powder | 1.38 | 7.76 | - | 2.39 | 2.52 | 1.73 | 93.37 |
| CWE | 2 | 68 | 0.39 | - | 1.25 | 2.29 | 96.08 |
| LMW | 0.3 | 22 | 3.11 | - | 5.39 | - | 91.49 |
| MMW | 1 | 35 | - | - | - | 1.25 | 98.74 |
| HMW | 4 | 71 | - | - | 5.11 | 4.62 | 90.27 |
The maximum response (Emax) of carbachol, 5-HT and CaCl derived from the respective concentration-response curve (CRC) in the presence of different treatment.
| Treatments | Carbachol | 5-HT | CaCl | |||
|---|---|---|---|---|---|---|
| Emax (%) | Emax (%) | Emax (%) | ||||
| + Vehicle control | 6 | 241.20 ± 24.41 | 5 | 85.24 ± 30.95 | 7 | 91.44 ± 31.11 |
| + HMW (2.5 mg/ml) | 5 | 44.52 ± 36.61∗∗∗∗ | 5 | 2.48 ± 3.41∗∗∗ | 5 | 37.75 ± 8.83∗∗∗ |
| + LMW (2.5 mg/ml) | 5 | 187.90 ± 26.88 | 6 | 69.91 ± 24.22 | 5 | 100.90 ± 18.10 |
| + CWE (2.5 mg/ml) | 6 | 165.00 ± 45.37∗ | 6 | 60.28 ± 31.64 | 5 | 54.48 ± 11.79∗ |
| + Ipratropium (30 nM) | 6 | 177.30 ± 46.88∗ | - | - | - | - |
| + Nifedipine (10 μM) | - | - | - | - | 5 | 21.83 ± 12.54∗∗∗∗ |